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Summary
Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the 
optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard 
chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer.
Methods The CONVERT trial was an open-label, phase 3, randomised superiority trial. We enrolled adult patients 
(aged ≥18 years) who had cytologically or histologically confirmed limited-stage small-cell lung cancer, Eastern 
Cooperative Oncology Group performance status of 0–2, and adequate pulmonary function. Patients were recruited 
from 73 centres in eight countries. Patients were randomly assigned to receive either 45 Gy radiotherapy in 30 twice-
daily fractions of 1·5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after 
commencing cisplatin–etoposide chemotherapy (given as four to six cycles every 3 weeks in both groups). The 
allocation method used was minimisation with a random element, stratified by institution, planned number of 
chemotherapy cycles, and performance status. Treatment group assignments were not masked. The primary endpoint 
was overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-
to-treat. A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered 
to be clinically significant to show superiority of the once-daily regimen. The study is registered with ClinicalTrials.
gov (NCT00433563) and is currently in follow-up.
Findings Between April 7, 2008, and Nov 29, 2013, 547 patients were enrolled and randomly assigned to receive 
twice-daily concurrent chemoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients). 
Four patients (one in the twice-daily group and three in the once-daily group) did not return their case report forms 
and were lost to follow-up; these patients were not included in our analyses. At a median follow-up of 45 months 
(IQR 35–58), median overall survival was 30 months (95% CI 24–34) in the twice-daily group versus 25 months 
(21–31) in the once-daily group (hazard ratio for death in the once daily group 1·18 [95% CI 0·95–1·45]; p=0·14). 
2-year overall survival was 56% (95% CI 50–62) in the twice-daily group and 51% (45–57) in the once-daily group 
(absolute difference between the treatment groups 5·3% [95% CI –3·2% to 13·7%]). The most common grade 3–4 
adverse event in patients evaluated for chemotherapy toxicity was neutropenia (197 [74%] of 266 patients in the 
twice-daily group vs 170 [65%] of 263 in the once-daily group). Most toxicities were similar between the groups, 
except there was significantly more grade 4 neutropenia with twice-daily radiotherapy (129 [49%] vs 101 [38%]; 
p=0·05). In patients assessed for radiotherapy toxicity, was no difference in grade 3–4 oesophagitis between the 
groups (47 [19%] of 254 patients in the twice-daily group vs 47 [19%] of 246 in the once-daily group; p=0·85) and 
grade 3–4 radiation pneumonitis (4 [3%] of 254 vs 4 [2%] of 246; p=0·70). 11 patients died from treatment-related 
causes (three in the twice-daily group and eight in the once-daily group).
Interpretation Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in 
patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both 
regimens. Since the trial was designed to show superiority of once-daily radiotherapy and was not powered to show 
equivalence, the implication is that twice-daily radiotherapy should continue to be considered the standard of care in 
this setting.
Funding Cancer Research UK (Clinical Trials Awards and Advisory Committee), French Ministry of Health, Canadian 
Cancer Society Research Institute, European Organisation for Research and Treatment of Cancer (Cancer Research 
Fund, Lung Cancer, and Radiation Oncology Groups).
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC-BY 4.0 license.
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Introduction
Small-cell lung cancer is characterised by its rapid tumour 
doubling time, early dissemination, and high response 
rate to both chemotherapy and radiotherapy. Of the 
42 000 patients in the UK and 225 000 in the USA 
diagnosed with lung cancer every year, 15% have small-cell 
lung cancer and 30% of those have limited-stage disease 
that can be encompassed within a tolerable radiotherapy 
field.1 Even in this early-stage disease, outcomes are poor, 
with median survival of 16–24 months after curative intent 
treatment and 2-year survival of less than 50%.2–4 Combined 
chemotherapy and thoracic radiotherapy is the standard 
treatment for limited-stage small-cell lung cancer. Results 
from two meta-analyses5,6 showed that the addition of 
radiotherapy to chemotherapy improves median survival, 
3-year survival, and local control. Subsequently, meta-
analyses of clinical trials investigating the optimal timing 
and sequencing of chemoradiotherapy have shown an 
advantage for early concurrent thoracic radiotherapy.7–11 
Furthermore, twice-daily radiotherapy was superior to 
once-daily radiotherapy in the landmark Intergroup 0096 
study.4 In that study, patients were randomly assigned to 
receive either 45 Gy once-daily (1·8 Gy per fraction) for 
5 weeks or 45 Gy twice-daily (1·5 Gy per fraction) for 
3 weeks. In both groups, radiotherapy was given 
concurrently, starting with the first cycle of chemotherapy. 
Twice-daily radiotherapy significantly improved 5-year 
overall survival compared with once-daily radiotherapy 
(26% vs 16%) and reduced the risk of thoracic relapse 
(36% vs 52%) but at the cost of increased severe radiation 
oesophagitis (32% vs 16%). Consequently, twice-daily 
radiotherapy concurrently with chemotherapy was adopted 
as a standard of care for limited-stage small-cell lung 
cancer.12 However, it is unclear whether twice-daily 
radiotherapy resulted in better outcomes because of the 
increase in the biologically effective dose of radiation or 
because of shorter overall treatment time, which is 
important in this rapidly proliferating disease. 
Radiotherapy techniques have evolved since the 
Intergroup 0096 study was designed in the late 1980s; 
specifically, the use of CT-planned conformal treatment 
and the omission of elective nodal irradiation to reduce 
normal tissue exposure and toxicity, particularly 
oesophagitis.
Although twice-daily radiotherapy concurrently with 
chemotherapy has produced the best outcomes so far, 
concerns about its toxicity, logistical issues in its delivery, 
and the low radiation dose in the control group of the 
Intergroup 0096 study, resulting in a very high (52%) 
local failure rate, have resulted in the poor adoption of 
this regimen and no consensus on the standard treatment 
to use in the routine setting.13 The authors of one study14 
suggested that the local control could be improved with a 
higher dose of once-daily radiotherapy. The CONVERT 
trial was therefore designed as a superiority trial to 
improve on the standard of care for limited-stage small-
cell lung cancer by comparing twice-daily radiotherapy to 
a higher dose of radiotherapy delivered once daily, given 
concurrently with chemotherapy.
Methods
Study design and participants
The CONVERT trial was an international, multicentre, 
open-label, randomised phase 3 superiority trial. Details 
of the trial design have been published previously.15 
Patients were recruited at 73 centres in eight countries 
Research in context
Evidence before this study
The role of thoracic radiotherapy is well established in the 
management of limited-stage small-cell lung cancer, and the 
standard of care in patients with good performance status is 
concurrent chemoradiotherapy. However, the optimal 
radiotherapy dose and fractionation remains controversial. 
One standard of care is twice-daily radiotherapy, which was 
shown to be superior to once-daily radiotherapy in a landmark 
Intergroup 0096 study in 1999. We searched PubMed and the 
abstracts of major conferences (such as the American Society of 
Clinical Oncology) with the terms “small cell lung cancer”, 
“limited-stage”, “radiotherapy (or irradiation)”, and 
“chemotherapy”, with no constraints imposed on the 
timeframe for the search, for randomised evidence to support 
this practice. We found only one relevant randomised clinical 
trial comparing once-daily and twice-daily radiotherapy.
Added value of this study
Although twice-daily radiotherapy has produced the best 
outcomes in these patients so far, concerns about its toxicity, 
logistical issues in the delivery of twice-daily radiotherapy, and 
the low radiation dose used in the control group of the 
Intergroup 0096 study have resulted in the poor adoption of 
this regimen and no consensus on the standard treatment to 
use in the routine setting. The CONVERT trial provides further 
evidence supporting the use of twice-daily radiotherapy in the 
routine setting and will help to standardise patient care. 
Furthermore, the results of this study show that in the era of 
modern radiotherapy techniques, the frequency and severity 
of acute and late radiation toxicities are lower than previously 
reported.
Implications of all the available evidence
Results from this study showed that twice-daily radiotherapy 
should be considered standard-of-care in patients with limited-
stage small-cell lung cancer. The implication for future research 
is that overall treatment duration of radiotherapy should be 
kept short when combined with chemotherapy. This Article 
provides updated information on expected treatment toxicity 
that clinicians can relay to their patients.
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(Belgium, Canada, France, Netherlands, Poland, 
Slovenia, Spain, and the UK; appendix pp 1–2).
Eligible patients were aged 18 years or older; had 
histologically or cytologically confirmed small-cell lung 
cancer with limited disease (as defined by the Veterans 
Administration Lung Cancer Study Group—ie, patients 
whose disease can be encompassed within a radical 
radiation portal);16 had an Eastern Cooperative Oncology 
Group performance status of 0–117 or performance 
status of 2 due to disease-related symptoms and not co-
morbidities (since small-cell lung cancer is characterised 
by rapid doubling time and central disease location, 
which can be associated with a sudden change in 
performance status); had no malignant pleural or peri-
cardial effusions; and had acceptable radiotherapy target 
volume (according to the local radiotherapist). Eligible 
patients had a maximum of one adverse biochemical 
factor (concentrations of serum alkaline phosphatase 
>1·5-times the upper limit of normal, serum sodium 
<lower limit of normal, and serum lactate dehydrogenase 
>the upper limit of normal), forced expiratory volume in 
1 s greater than 1 L or 40% predicted value, and transfer 
factor for carbon monoxide greater than 40% predicted 
value. Patients with a previous history of malignancy in 
the past 5 years (except for non-melanomatous skin or in-
situ cervix carcinoma) and those with previous or 
concomitant illness or treatment that, in the opinion of 
the investigator, would interfere with the trial treatments 
or comparisons were excluded.
Participants gave written informed consent and the 
study was done according to the Declaration of Helsinki 
and Good Clinical Practice Guidelines. The trial was 
reviewed in the UK by the National Research Ethics 
Service Committee North West–Greater Manchester 
Central, which granted ethics approval for the study 
on Dec 21, 2007 (REC reference: 07/H1008/229). The 
protocol was also approved by the institutional review 
board or research ethics committee in each country and 
at each study centre.
Randomisation and masking
Patients were randomly assigned (1:1) to one of the two 
treatment groups (twice-daily vs once-daily radiotherapy). 
Allocation to treatment group was done by phone call or 
fax from the recruiting centre to the Manchester 
Academic Health Science Centre Trials Coordination 
Unit. The allocation method used was minimisation with 
a random element using a bespoke computer application. 
The factors controlled for in the allocation were 
institution, planned number of chemotherapy cycles 
(four vs six), and performance status (0–1 vs 2). Patients 
and investigators were not masked to treatment 
allocation. 
Procedures
At baseline, all patients underwent baseline investi-
gations, which included physical examination, chest 
radiograph, CT scan of the thorax and upper abdomen, 
CT or MRI of the brain, full blood count, biochemical 
profile, and lung function tests. PET/CT scans were 
allowed but not mandatory. Staging was done using the 
Union for International Cancer Control/American Joint 
Committee on Cancer classification system.18
Patients were randomly assigned to receive radio-
therapy either twice-daily (45 Gy in 30 twice-daily 
fractions of 1·5 Gy, with a minimum of 6 h between 
fractions, over 19 days, on 5 consecutive days a week) or 
once-daily (66 Gy in 33 daily fractions of 2 Gy over 
45 days, on 5 consecutive days a week), concurrently 
with chemo therapy. Chemotherapy was started within 
4 weeks of randomisation  and consisted of four to 
six cycles of cisplatin and etoposide every 3 weeks in 
both groups (etoposide 100 mg/m² intravenously on 
days 1–3 and cisplatin 75 mg/m² intravenously on day 1, 
or etoposide 100 mg/m² intravenously on days 1–3 and 
cisplatin 25 mg/m² intravenously on days 1–3). Each 
centre had to elect to prescribe four or six cycles for all 
eligible trial patients. The first cycle of chemotherapy 
was given before radiotherapy and the second was 
given concurrently with radiotherapy if no delay with 
chemotherapy occurred. No later than 6 weeks after the 
last cycle of chemotherapy, patients without evidence of 
progressive disease on the CT scan and with no clinical 
evidence of brain metastases were offered prophylactic 
cranial irradiation.
Radiotherapy commenced on day 22 of cycle one of 
chemotherapy, coinciding with cycle two of chemotherapy 
in patients not experiencing chemotherapy delay due to 
toxicity. 3D conformal radiotherapy was mandatory and 
elective nodal irradiation was not permitted. The total 
dose was prescribed at the International Commission on 
Radiation Units and Measurements reference point. 
Intensity-modulated radiotherapy and PET/CT planning 
was permitted but not mandated. The protocol specified 
that if dose constraints to the organs at risk could not be 
met, the dose delivered could be decreased accordingly. 
The policy for chemotherapy was to delay and give at full 
dose later, rather than give at a reduced dose. However, 
we recommended a chemotherapy treatment delay of 
more than 7 days for grade 4 febrile neutropenia, grade 4 
thrombocytopenia requiring medical intervention, or 
grade 2 or worse bleeding with thrombocytopenia; for the 
first episode of such an event, we recommended full-dose 
chemotherapy and granulocyte colony-stimulating factor 
support, or a 20% dose reduction. In case of a second 
episode, we recommended a 30% dose reduction. If a 
third episode occurred, the patient was removed from 
the trial. 
A radiotherapy quality assurance programme was set 
up to ensure the robustness of the radiotherapy 
procedures, and the details of the programme have been 
reported previously.15 The programme was managed by 
the UK National Cancer Research Institute Radiotherapy 
Trials Quality Assurance Team.
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On completion of study treatment, patients were 
followed up weekly until the resolution of acute side-
effects, then every 3 months until 1 year, and every 
6 months for 5 years. A CT scan of the thorax and 
abdomen was done at 4 weeks after cycle four (even 
if six cycles were given). Subsequently, during follow-
up at 6 and 12 months after randomisation, 
investigations included physical evaluation, reporting 
of adverse events, and a CT scan of the thorax and 
abdomen. Follow-up investigations were done 
according to local policy.
Outcomes
The primary outcome of the study was overall survival, 
defined as time from randomisation until death from any 
cause. Secondary outcomes included compliance with 
chemotherapy and radiotherapy (defined as dose intensity 
delivered), acute toxicity (defined as toxicity occurring 
between the start of treatment and up to 3 months after 
completion of treatment, and assessed according to the 
Common Terminology Criteria for Adverse Events 
[version 3.0]), late toxicity (according to the Common 
Terminology Criteria for Adverse Events [version 3.0]),19 
and local and metastatic progression-free survival 
(calculated from date of randomisation to date of first 
clinical or radiological evidence of progressive disease at 
the primary site or distant sites). With regard to toxicity, 
frequencies of worst recorded grade of toxicity in the 
respective time periods were recorded. Response rate was 
another secondary outcome but it was not analysed 
because interpretation of CT imaging would have 
been too complex after concurrent chemoradiotherapy. 
The study also had post-hoc exploratory translational 
objectives, which will be reported at a later date. All 
serious adverse events were reported to the trial 
coordinating centre and were assessed for causality and 
expectedness, both locally by the Principal Investigator 
and centrally by the Chief Investigator.
Statistical analysis
Our hypothesis was that overall survival in the once-daily 
chemoradiotherapy group would be superior to that of 
the twice-daily group. A 12% higher overall survival at 
2 years in the once-daily group versus the twice-daily 
group was considered to be clinically significant to show 
superiority of the once-daily regimen. Overall and 
progression-free survival were estimated with the 
Kaplan-Meier method, and between-group comparisons 
Figure 1: Trial profile
*One patient withdrew consent for twice-daily radiotherapy. †Dose constraints to organs at risk not met in four patients and twice-daily radiotherapy given in error 
to two patients. ‡Six patients did not receive any chemotherapy and two patients died during cycle one before toxicity assessment. ¶Seven patients did not receive 
any chemotherapy and three patients died during cycle one before toxicity assessment. Numbers assessed and ineligible are unavailable because screening logs were 
not completed by all centres. 
274 allocated to receive twice-daily 
 concurrent chemoradiotherapy
25 did not receive concurrent 
 chemoradiotherapy (20 no radiotherapy and 
 5 received sequential chemoradiotherapy)      
 7 progressive disease or died                                           
 5 tumour volume too large           
 4 randomisation error              
 4 patient withdrawal or lost to follow-up    
 3 chemotherapy toxicity          
 2 oncologist decision
249 received concurrent chemoradiotherapy
      1 received once-daily chemoradiotherapy
1 lost to follow-up (did not return case report
   form)
273 included in survival analysis
254 included in radiotherapy toxicity analysis 
 (concurrent and sequential 
 chemoradiotherapy)
266 included in chemotherapy
 toxicity analysis‡
273 allocated to receive once-daily 
 concurrent chemoradiotherapy
33 did not receive concurrent 
      chemoradiotherapy (26 no radiotherapy, 
      6 received sequential chemoradiotherapy, 
      and 1 unknown)      
 10 progressive disease or died                                
 7 oncologist decision    
 7 tumour volume too large   
 5 patient withdrawal or lost to follow-up
 3 randomisation error
 1 unknown
                 
            
240 received concurrent chemoradiotherapy
      6 received twice-daily chemoradiotherapy
3 lost to follow-up (did not return case report
   form)     
270 included in survival analysis
246 included in radiotherapy toxicity analysis 
 (concurrent and sequential 
 chemoradiotherapy)
263 included in chemotherapy
 toxicity analysis¶
547 patients randomly assigned  
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evaluated by the log-rank test with stratification for 
institution, planned number of chemotherapy cycles 
(four vs six), and performance status (0–1 vs 2). The 
number of events required to detect a hazard ratio (HR) 
for death of 0·7 with an α level (two-sided) of 0·05 and 
80% power (ie, an increase in 2-year survival from 44% in 
the twice-daily radiotherapy group to 56% in the once-
daily radiotherapy group) was 247. An additional 5% was 
added to the sample size of 506 patients to allow for 
ineligible patients, giving a total recruitment target of 
532 patients. The primary survival outcome was analysed 
using the modified intention-to-treat principle, because 
four cases provided no follow-up data and hence were 
censored at time zero. Further details about the statistical 
analysis are available in the protocol.15 All randomly 
assigned patients who were treated with at least one 
study dose of chemotherapy and who were alive at the 
time of the first toxicity assessment were included in the 
safety analysis. Data were collected at each study site and 
monitored by the independent data monitoring 
committee. We submitted reports to the independent 
data monitoring committee on an annual basis, 
commencing 12 months after the first patient was 
randomly assigned. The statistical package used for the 
analyses was Stata (version 13.1).
This trial is registered with ISRCTN, number 91927162, 
and ClinicalTrials.gov, number NCT00433563.
Role of the funding source
Cancer Research UK reviewed and approved the study 
design. None of the funders had a role in data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility for the decision 
to submit for publication.
Results
Between April 7, 2008, and Nov 29, 2013, we recruited 
547 patients from 73 centres in eight countries. We 
randomly assigned 274 patients to receive twice-daily 
chemoradiotherapy and 273 to receive once-daily chemo-
radiotherapy. The modified intention-to-treat survival 
analysis included 543 patients (273 in the twice-daily 
chemo radiotherapy group and 270 in the once-daily 
chemoradiotherapy group) because four patients were 
lost to follow-up (centres did not return their case report 
forms; (figure 1). Table 1 shows the baseline characteristics 
of the participants. The median age at randomisation 
was 62 years (IQR 29–84) in the twice-daily group and 
63 years (34–81) in the once-daily group, with 83 (15%) of 
547 patients being older than 70 years (32 [12%] in the 
twice-daily group and 51 [19%] in the once-daily group). 
More than 95% of patients overall had a performance 
status of 0–1. Less than 2% of patients were never 
smokers, almost two-thirds were former smokers, and 
just over a third were current smokers (table 1). 312 (57%) 
of 547 patients were staged with PET/CT, and 426 (78%) 
of 547 were stage III according to the Union for 
International Cancer Control classification (table 1).
The number of planned cycles of chemotherapy was 
four for most patients (table 1). Almost 60% of patients 
actually received four cycles and a further 20% received 
six cycles of chemotherapy (table 2). 
At the data analysis cutoff in March 1, 2016, the median 
follow-up was 45 months (IQR 35–58) for those still alive. 
Twice-daily radiotherapy 
(n=274)
Once-daily radiotherapy 
(n=273)
Age (years) 62 (29–84) 63 (34–81)
Sex
Male 147 (54%) 150 (55%)
Female 127 (46%) 123 (45%)
Ethnicity
White 262 (96%) 265 (97%)
African 1 (<1%) 1 (<1%)
Asian 1 (<1%) 4 (2%)
Other 6 (2%) 3 (1%)
Not known 4 (2%) 0
Eastern Cooperative Oncology Group performance status
0 125 (46%) 123 (45%)
1 137 (50%) 142 (52%)
2 9 (3%) 8 (3%)
Not known* 3 (1%) 0
Smoking history†
Never smoker 3 (1%) 4 (2%)
Former smoker 174 (64%) 163 (60%)
Current smoker 94 (34%) 106 (39%)
Not known 3 (1%) 0
Adverse biochemical factors
Elevated lactate dehydrogenase 69 (25%) 60 (22%)
Hyponatraemia 57 (21%) 53 (19%)
Elevated alkaline phosphate 5 (2%) 6 (2%)
PET/CT staging
Yes 157 (57%) 155 (57%)
No 113 (41%) 118 (43%)
Not known 4 (2%) 0
UICC/AJCC stage18
I 1 (<1%) 3 (1%)
II 34 (12%) 48 (18%)
III 219 (80%) 207 (76%)
Not known 20 (7%) 15 (6%)
Gross tumour volume (cc) 81·6 (1·6–635·1) 85·6 (0·5–593·0)
Number of chemotherapy cycles planned
Four 188 (69%) 183 (67%)
Six 86 (31%) 90 (33%)
Data are median (IQR) or n (%). UICC/AJCC=Union for International Cancer Control/American Joint Committee on 
Cancer. *Eastern Cooperative Oncology Group Performance Status was not recorded on the source documentation 
and case report form in three cases at baseline; in all three cases, the performance score was recorded as 0–1 on the 
randomisation form. †Never smokers defined as adults who have never smoked a cigarette or who smoked fewer 
than 100 cigarettes in their entire lifetime; former smokers defined as adults who have smoked at least 
100 cigarettes in their lifetime but say they currently do not smoke; current smokers defined as adults who have 
smoked 100 cigarettes in their lifetime and currently smoke cigarettes every day (daily) or on some days (non-daily).
Table 1: Baseline characteristics
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164 (60%) of 273 patients in the twice-daily group had 
died, compared with 176 (65%) of 270 patients in the 
once-daily group.
In our survival analysis (which included 273 patients in 
the twice-daily group and 270 in the once-daily group), 
median overall survival was 30 months (95% CI 24–34) in 
the twice-daily group and 25 months (21–31) in the once-
daily group (hazard ratio 1·18 [95% CI 0·95–1·45]; p=0·14; 
figure 2A). 2-year overall survival was 56% (95% CI 50–62) 
in the twice-daily group and 51% (45–57) in the once-daily 
group (absolute difference between the treatment groups 
5·3% [95% CI –3·2% to 13·7%]). 5-year  overall survival 
was 34% (95% CI 27–41) in the twice-daily group and 31% 
(25–37) in the once-daily group (absolute difference 2·8% 
[95% CI –6·4% to 12·0%]). In the twice-daily group versus 
the once-daily group, causes of death were lung cancer 
(152 vs 146), intercurrent deaths (six vs 14), treatment-
related (three vs eight), and cardiovascular (three vs eight); 
causes of the 12 treatment-related deaths were radiation 
pneumonitis (one vs two), dementia possibly related to 
prophylactic cranial irradiation (none vs one), neutropenic 
sepsis (one vs three), septic shock (one vs none), bronchial 
pneumonia (none vs two), and peripheral vascalar 
ischaemia (one vs none). 
25 (9%) of 273 patients in the twice-daily radiotherapy 
group and 33 (12%) of 270 in the once-daily radiotherapy 
group did not receive concurrent chemoradiotherapy 
(figure 1), giving compliance rates of 91% in the twice-
daily group and 88% in the once-daily group. Less than 
10% of patients did not receive any radiotherapy (20 [7%] 
in the twice-daily group and 26 [10%] in the once-daily 
group; figure 1, table 2). Of the patients who received 
radiotherapy, intensity-modulated radiotherapy was 
delivered to 40 (16%) of 254 participants in the twice-daily 
group versus 43 (17%) of 247 participants in the once-daily 
group. Prophylactic cranial irradiation was delivered to 
229 (84%) of 274 vs 220 (81%) of 273 participants (table 2). 
More patients received the full dose of radiotherapy in the 
twice-daily group than in the once-daily group (p<0·0001; 
table 3). The optimal number of fractions, as defined in 
the protocol,15 (30 fractions in the twice daily group and 33 
in the once daily group) were delivered in 213 (86%) of 
249 patients in the twice-daily group and 192 (80%) of 
240 patients in the once-daily group (p=0·10). 
Radiotherapy was delivered over the planned overall 
treatment time of 19 days in 158 (63%) of 249 patients in 
the twice-daily group and over the planned overall 
treatment time of 45 days in 114 (48%) of 240 patients in 
the once-daily group (p=0·0004). Protocol deviations and 
violations were mainly due to logistical reasons, such as 
public holidays.
At the time of analysis, 181 (66%) of 273 patients in the 
twice-daily group and 189 (70%) of 270 patients in the 
once-daily group had disease progression (p=0·26). 
Median progression-free survival was 15·4 months 
(95% CI 13·7–19·8) in the twice-daily group and 
14·3 months (12·0–17·0) in the once-daily group (hazard 
ratio 1·12 [95% CI 0·92–1·38]; p=0·26). Median local 
progression-free survival was 20·7 months (95% CI 
16·1–27·9) in the twice-daily group versus 17·9 months 
(15·3–21·7) in the once daily group (figure 2B) and median 
metastatic progression-free survival was 20·2 months 
(95% CI 15·9–25·3) versus 16·6 months (13·7–21·8). 
The difference between groups for local progression-
free survival (p=0·20) and metastatic progression-free 
survival (p=0·24) was not significant (figure 2). There was 
no notable difference between groups in treatment 
received at the time of progression (appendix p 4).
Chemotherapy toxicity was assessed in 266 (97%) of 
273 patients in the twice-daily group and 263 (97%) 
of 270 patients in the once-daily group, who had received 
at least one cycle of chemotherapy and who were alive 
at the time of the first toxicity assessment (figure 1, 
table 4). Radiotherapy toxicity was assessed in 254 (93%) 
of 273 patients in the twice-daily group and 246 (91%) of 
270 patients in the once-daily group who had received 
either concurrent or sequential chemoradiotherapy 
(figure 1, table 4).
Twice-daily 
radiotherapy (n=274)
Once-daily radiotherapy 
(n=273)
p value*
Chemotherapy cycles delivered 
(all patients)
0·89
0 6 (2%) 7 (3%)
1 15 (6%) 15 (6%)
2 8 (3%) 6 (2%)
3 23 (8%) 24 (9%)
4 161 (59%) 156 (57%)
5 5 (2%) 12 (4%)
6 56 (20%) 53 (19%)
Radiotherapy treatment 0·60
Concurrent chemoradiotherapy 249 (91%) 240 (88%)
Sequential chemoradiotherapy 5 (2%) 6 (2%)
No radiotherapy 20 (7%) 26 (10%)
Not known ·· 1 (<1%)
Chemotherapy cycles delivered in patients who received concurrent chemoradiotherapy†
1 3/249 (1%) 1/240 (<1%)
2 5/249 (2%) 5/240 (2%)
3 21/249 (8%) 20/240 (8%)
4 161/249 (66%) 150/240 (63%)
5 5/249 (2%) 12/240 (5%)
 6 54/249 (21%) 52/240 (22%)
Intensity-modulated radiotherapy 0·59
Yes 40/254‡ (16%) 43/247‡ (17%)
Not known ·· 1 (<1%) 
Prophylactic cranial irradiation 229 (84%) 220 (81%) 0·36
Data are n (%) or n/N (%). *All p values were calculated with χ² tests (except for number of cycles, which is a Wilcoxon 
rank sum test). †The denominator in each group is the number of patients who received concurrent chemoradiotherapy. 
‡The denominator in each group is the number of patients who received radiotherapy.
Table 2: Treatment delivered
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The most common grade 3–4 adverse event was 
neutropenia (affecting 197 [74%] of 266 patients in the 
twice-daily group vs 170 [65%] of 263 in the once-daily 
group). The frequencies of most adverse events recorded 
were similar in both groups, with the exception that 
significantly more grade 4 neutropenia was recorded in 
the twice-daily group than in the once-daily group 
(129 [49%] vs 101 [38%]; p=0·05). However, grade 3–5 
febrile neutropenia did not differ significantly between 
the two groups (table 4). Acute radiotherapy toxicity was 
similar in both groups: grade 3–4 oesophagitis was 
reported in 47 (18%) of 254 patients in the twice-daily 
group and 47 (19%) of 246 patients in the once-daily group. 
11 patients developed grade 3–5 radiation pneumonitis 
(five in the twice daily group and six in the once daily 
group), of whom three patients died within 3 months of 
radiotherapy (two in the once-daily group and one in the 
twice-daily group, one of whom received sequential rather 
than concurrent radiotherapy; table 4, appendix p 3). 
Regarding late toxicity, four patients in the once-daily 
group developed grade 3 oesophagitis, one of whom had 
an oesophageal stricture. Six patients in each group 
developed grade 3–4 pneumonitis, and five patients 
(three in the twice-daily group and two in the once-daily 
group) developed grade 3 pulmonary fibrosis (table 5).
Discussion
Our results show that once-daily radiotherapy did not 
improve overall survival in patients with limited-stage 
small-cell lung cancer and good performance status, 
compared with twice-daily radiotherapy, when given 
concurrently with chemotherapy. Radiotherapy treatment 
delivery was superior in the twice-daily group. Further-
more, both acute and late toxicities were similar and 
lower than expected with both regimens. 
However, although results are unable to show 
superiority of the once-daily radiotherapy regimen, the 
CONVERT trial should have a major effect on the 
standardisation of chemoradiotherapy in this disease 
group—a treatment that has been the subject of 
controversy since the publication of the Intergroup 0096 
study.4,13 Overall survival with both regimens were 
higher than the survival results reported in the 
Intergroup 0096 study. In CONVERT, 2-year survival 
for twice-daily and once-daily radiotherapy was 56% 
and 51%, versus 47% and 41% in the Intergroup 0096 
study.4 CONVERT was not an equivalence study (and 
was not powered for equivalence) so it cannot be 
concluded that the two regimens have the same efficacy. 
Furthermore, the 2-year survival of 56% achieved in the 
control group with twice-daily radiotherapy is the 
same survival that was projected for the experimental 
group. The better-than-expected performance of both 
Figure 2: Overall and progression-free survival
(A) Overall survival. (B) Local progression-free survival. (C) Metastatic 
progression-free survival. HR=hazard ratio. 
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groups might be explained by several changes in the 
management of small-cell lung cancer since the 
publication of the Intergroup study, including PET/CT 
staging in more than half of patients, the use of modern 
and precise radiotherapy techniques, and improvements 
in supportive care. These results, together with several 
meta-analyses and systematic overviews, support the 
use of short overall radiotherapy treatment time to avoid 
early cancer cell repopulation.7–11 One of the systematic 
overviews also identified that time from the start of any 
treatment to completion of radiotherapy is a key variable 
in predicting outcome.20 Although not significant, 2-year 
overall survival was slightly higher in the twice-daily 
group than in the once-daily group, which could possibly 
be a result of improved delivery of treatment in the 
Twice-daily group Once-daily group p value
Grade 1–2 Grade 3 Grade 4 Grade 5 Grade 1–2 Grade 3 Grade 4 Grade 5
Adverse events in the population assessed for chemotherapy toxicity (n=266 in the twice-daily group; n=263 in the once-daily group) 
Nausea 172 (65%) 23 (9%) ·· ·· 171 (65%) 26 (10%) ·· ·· 0·63
Vomiting 105 (40%) 13 (5%) ·· ·· 95 (36%) 13 (5%) ·· ·· 0·99
Mucositis 88 (33%) 3 (1%) ·· ·· 87 (33%) 5 (2%) 1 (<1%) ·· 0·34
Fatigue 212 (80%) 31 (12%) ·· ·· 216 (82%) 31 (12%) 2 (1%) ·· 0·77
Neuropathy (motor) 12 (5%) 1 (<1%) ·· ·· 15 (6%) 2 (1%) ·· ·· 0·62
Neuropathy (sensory) 63 (24%) 3 (1%) 1 (<1%) 1 (<1%) 61 (23%) 5 (2%) ·· ·· >0·99
Infection 43 (16%) 27 (10%) 7 (3%) ·· 52 (20%) 27 (10%) 2 (1%) 2 (1%) 0·52
Anaemia 194 (73%) 32 (12%) 1 (<1%) ·· 184 (70%) 34 (13%) 1 (<1%) ·· 0·72
Febrile neutropenia NA 49 (18%) 13 (5%) 1 (<1%) NA 38 (14%) 8 (3%) 3 (<1%) 0·13
Neutropenia 38 (14%) 68 (26%) 129 (49%) ·· 47 (18%) 69 (26%) 101 (38%) ·· 0·05
Anorexia 135 (51%) 18 (7%) ·· ·· 129 (49%) 21 (8%) ·· ·· 0·60
Other* 150 (57%) 65 (24%) 9 (3%) 1 (<1%)† 177 (67%) 44 (17%) 8 (3%)‡ 1 (<1%) 0·02
Adverse events in the population assessed for radiotherapy toxicity (n=254 in the twice-daily group; n=246  in the once-daily group) 
Oesophagitis 159 (63%) 46 (18%) 1 (<1%) ·· 135 (54%) 47 (19%) ·· ·· 0·85
Pneumonitis 51 (20%) 3 (1%) 1 (<1%) 1 (<1%) 49 (19%) 3 (1%) 1 (<1%) 2 (1%) 0·70
Data are n (%). The radiotherapy toxicity population was used to analyse the prevalence of these adverse events because it would not be possible to report radiotherapy-related toxicity in patients who did not 
receive radiotherapy. NA=not applicable. *Other grade 3 reported toxicities included diarrhoea (n=7), hyponatremia (n=1), urinary retention (n=5), dysphagia (n=5), and lymphopenia (n=6) in the once-daily group; 
and diarrhoea (n=3), constipation (n=7), hyponatremia (n=1), dysphagia (n=8), lymphopenia (n=8), dyspnoea (n=8), and leucopenia (n=4) in the twice-daily group. Other grade 4 reported toxicities included 
pulmonary embolism (n=4), hyponatremia (n=2), dyspnoea (n=1), and myocardial infarction (n=1) in the once-daily group; and pulmonary embolism (n=2), hyponatremia (n=3), lymphopenia (n=3), and fast atrial 
fibrillation (n=1) in the once-daily group). †Two deaths (peripheral arterial ischaemia [n=1] and septic shock [n=1]). ‡Two deaths (peripheral arterial ischaemia [n=1] in the twice-daily group and dementia possibly 
related to prophylactic cranial irradiation [n=1] in the once-daily group). 
Table 4: Acute adverse events (≤3 months after completion of study treatment)
Twice-daily group (n=248) Once-daily group (n=233) p value*
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Dermatitis 15 (6%) ·· ·· 17 (7%) ·· ·· ··
Oesophagitis 29 (12%) ·· ·· 39 (17%) 4 (2%) ·· 0·06
Oesophageal 
stricture or fistula
8 (3%) ·· ·· 6 (3%) 1 (<1%) ·· 0·48
Pulmonary fibrosis 119 (48%) 3 (1%) ·· 106 (46%) 2 (1%) ·· >0·99
Pneumonitis 71 (29%) 5 (2%) 1 (<1%) 70 (30%) 5 (2%) 1 (<1%) 0·90
Myelitis 1 (<1%)† ·· ·· 8 (3%)† ·· ·· ··
Other 131 (53%) 20 (8%) 3 (1%) 113 (49%) 18 (8%) 2 (1%) 0·78
Data are n (%). *p values calculated for grade 3–4 adverse events. †All cases of myelitis were grade 1 adverse events.  
Table 5: Late adverse events (>3 months after study treatment)
Dose (Gy) Number of fractions Overall treatment time (days)
<44 44–46* >46 <60 60–62 64–68* <28 28–29 30† >30 <30 30–32 33† >33 <19 19‡ 20–21§ >21¶ <45 45‡ 46–47§ >47¶
Twice-daily 
radiotherapy 
(n=249)
1 
(<1%)
245 
(98%)
3 
(1%)
·· ·· ·· 12 
(5%)
23 
(9%)
213 
(86%)
1 
(<1%)
·· ·· ·· ·· 15 
(6%)
158 
(63%)
24 
(10%)
52 
(20%)
·· ·· ·· ··
Once-daily 
radiotherapy 
(n=240)
·· ·· ·· 22 
(9%)
19 
(8%)
199 
(83%)
·· ·· ·· ·· 16 
(7%)
31 
(13%)
192 
(80%)
1 
(<1%)
·· ·· ·· ·· 41 
(17%)
114 
(48%)
43 
(18%)
42 
(18%)
Data are n (%). *Full dose. †Optimal number of fractions, as defined in the protocol. ‡Planned overall treatment time. §Deviation. ¶Violation. 
Table 3: Radiotherapy treatment delivered in patients receiving concurrent chemoradiotherapy (as per protocol)
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twice-daily group, with more patients receiving full-dose 
radiotherapy, the optimal planned number of fractions, 
and treatment delivered over the optimal treatment 
time. Another reason why treatment delivery was 
superior in the twice-daily group is because of the lower 
overall dose of radiotherapy in this group, which meant 
it was possible to achieve the protocol dose constraints 
for organs at risk, such as lung and spinal cord, in a 
greater proportion of patients than in the once-daily 
group. A further advantage of the twice-daily regime is 
that it halves the radiotherapy treatment time (from 
45 days to 19 days) and reduces the number of fractions 
(from 33 to 30) compared with the once-daily regimen. 
Although no formal health economic analysis has been 
done as part of this study, the delivery of twice-daily 
radiotherapy could lead to cost savings, especially if 
patients require hospital transport to attend radiotherapy 
appointments.
Overall, the frequency and severity of acute and late 
radiation toxicities were lower than expected, probably 
because of the use of modern radiotherapy techniques, 
including 3D radiotherapy or intensity-modulated radio-
therapy, and treatment of involved fields with regard to 
nodal disease. In the Intergroup 0096 trial,4 patients were 
treated with outdated radiotherapy techniques including 
elective nodal irradiation, which would have resulted in 
higher radiation exposure of normal tissues than in this 
trial. Indeed, the high rate of severe acute oesophagitis 
(32% with twice-daily radiotherapy) in the Intergroup 
study has been cited as the main reason for poor adoption 
of twice-daily radiotherapy.13 By contrast, less than 20% of 
patients had severe oesophagitis in the CONVERT study 
and only one patient developed an oesophageal stricture 
requiring intervention. Radiation pneumonitis was not 
specifically reported in the Intergroup 0096 study, but in 
this trial very few (<3%) patients had severe radiation 
pneumonitis or severe pulmonary fibrosis. The lower 
than anticipated toxicity rates and rates of local failure 
reported in this study suggest that radiotherapy treatment 
delivered concurrently with chemotherapy could be 
intensified further—for example, by means of dose 
escalation or hypofractionation.
A limitation of this study is that although we did not 
mandate an upper age limit—with the aim to gather 
much needed evidence about the outcome of elderly 
patients treated with concurrent chemoradiotherapy—
only 15% of the patients included were older than 
70 years. Data for patients older than 70 years 
participating in CONVERT was presented at the 
International Association for the Study of Lung Cancer 
17th World Conference on Lung Cancer in Vienna, 
Austria, in 2016, and the results of this analysis will be 
presented in a separate report. Elderly patients have 
been reported to be less likely to receive concurrent 
chemoradiotherapy than their younger counterparts, 
which is mainly due to insufficient high-quality evidence 
to support the use of this potentially toxic treatment.21 
Another limitation is that the majority of patients 
enrolled in both groups were white, and therefore the 
results of the study might not be applicable to other 
ethnicities.
To our knowledge, CONVERT is the largest study 
completed investigating thoracic radiotherapy in limited-
stage small-cell lung cancer, and the first clinical trial 
in this group of patients to report on the outcome of 
patients treated with modern radiotherapy techniques 
incorporating a quality assurance programme. It was 
possible to complete this study because of the interest, 
enthusiasm, and collaborative efforts of a large number 
of investigators from many different countries. The key 
to completing accrual was to include a large number 
of recruiting sites. Furthermore, by contrast with US 
practice, concurrent chemoradiotherapy is not always 
adopted as the standard of care for limited-stage small-
cell lung cancer in Europe, and the study provided an 
incentive for centres to adopt and set up concurrent 
treatment protocols.
Given the importance of keeping overall treatment time 
as short as possible, future studies could investigate dose-
escalated twice-daily or hypofractionated radio therapy 
concurrently with chemotherapy. Further data for the 
outcome of patients treated with high-dose 2 Gy per 
fraction treatment will be provided by the ongoing CALGB 
30610/RTOG 0538 study (NCT00632853). The upcoming 
analysis of the CONVERT translational studies, including 
the prognostic role of baseline circulating tumour cells, 
could provide data for relevant biological stratification 
factors that can be used prospectively in future studies.
In conclusion, the results of CONVERT show that 
there were no significant differences in survival and no 
major differences in toxicity between twice-daily and 
once-daily radiotherapy. However, since the trial was 
designed to show superiority of once-daily radiotherapy 
and not powered to show equivalence, twice-daily 
radiotherapy should continue to be considered 
standard-of-care. Furthermore, twice-daily radiotherapy 
concurrently with chemotherapy is well tolerated, with 
better compliance and shorter treatment time than once-
daily treatment. From a pragmatic perspective, once-
daily radiotherapy could be considered when delivery 
of twice-daily radiotherapy is impossible because of 
departmental logistics or patient choice.
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